B Joseph Elmunzer, James M Scheiman, Glen A Lehman, Amitabh Chak, Patrick Mosler, Peter D R Higgins, Rodney A Hayward, Joseph Romagnuolo, Grace H Elta, Stuart Sherman, Akbar K Waljee, Aparna Repaka, Matthew R Atkinson, Gregory A Cote, Richard S Kwon, Lee McHenry, Cyrus R Piraka, Erik J Wamsteker, James L Watkins, Sheryl J Korsnes, Suzette E Schmidt, Sarah M Turner, Sylvia Nicholson, Evan L Fogel
BACKGROUND: Preliminary research suggests that rectally administered nonsteroidal antiinflammatory drugs may reduce the incidence of pancreatitis after endoscopic retrograde cholangiopancreatography (ERCP). METHODS: In this multicenter, randomized, placebo-controlled, double-blind clinical trial, we assigned patients at elevated risk for post-ERCP pancreatitis to receive a single dose of rectal indomethacin or placebo immediately after ERCP. Patients were determined to be at high risk on the basis of validated patient- and procedure-related risk factors...
April 12, 2012: New England Journal of Medicine